Exposure to Di-2-ethylhexyl phthalate (DEHP) and infertility in women, NHANES 2013-2016.

Di-2-ethylhexyl phthalate (DEHP) exposure is widespread in the general population and previous research has suggested that it contains endocrine-disrupting properties that can adversely affect the reproductive health system. The objective of this study was to use the 2013-2016 National Health and Nutrition Examination Survey (NHANES) data to assess the potential association between DEHP exposure and infertility in women. Using a nationally representative, cross-sectional study design, we used multiple logistic regression to measure the association of urinary metabolites of DEHP with self-reported history of infertility among women.

Dentin Phosphophoryn-Derived Peptide Promotes Odontoblast Differentiation In Vitro and Dentin Regeneration In Vivo.

The purpose of the present study was to investigate the effect of a peptide (i.e., SESDNNSSSRGDASYNSDES) derived from dentin phosphophoryn (DPP) with arginine-glycine-aspartic acid (RGD) motifs on odontoblast differentiation in vitro and to compare it with calcium hydroxide-a material used conventionally for vital pulp therapy-in terms of reparative dentin formation and pulp inflammation in vivo.

Case of Neonatal Fatality from Neuromuscular Variant of Glycogen Storage Disease Type IV.

Glycogen storage disease type IV (GSD-IV), or Andersen disease, is a rare autosomal recessive disorder that results from the deficiency of glycogen branching enzyme (GBE). This in turn results in accumulation of abnormal glycogen molecules that have longer outer chains and fewer branch points. GSD-IV manifests in a wide spectrum, with variable phenotypes depending on the degree and type of tissues in which this abnormal glycogen accumulates.

Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease.

Background: Cross-reactive immunological material-negative (CRIM-negative) infantile Pompe disease (IPD) patients develop an immune response against enzyme replacement therapy (ERT) with alglucosidase alfa that nullifies ERT efficacy. Prophylactic immune tolerance induction (ITI) with rituximab, methotrexate, and IVIG successfully prevents development of deleterious rhGAA IgG antibodies; however, safety, likelihood of success, and long-term efficacy of ITI in a larger cohort remain unknown.

Methods: Clinical data were analyzed for 19 CRIM-negative IPD patients who received ITI with rituximab, methotrexate, and IVIG in the ERT-naive setting (ERT+ITI) and compared to a historical cohort of 10 CRIM-negative IPD patients on ERT monotherapy.